Price
$76.45+55.54%Social Signal Score
Analyst Ratings
25 analystsRevenue
$498.00M-29.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Guillermo Novo
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Employees
- 2,800
- Beta
- 0.36
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.50
Financials
Revenue
$498.00M-29.3%Net Income
$-16.00MEBITDA
$75.00M-29.9%Free Cash Flow
$38.00MEPS (diluted)
$-0.35Shares Outstanding (diluted)
46.00M-25.8%Operating Expenses
$127.00MCash & Debt
$480.00MReturn of Capital
$19.00MRevenue by Segment (annual)
$1.30BDividend per Share
$0.42Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.86B | $4.00M | $0.09 |
| 2025 | $1.82B | $-845.00M | $-18.37 |
| 2024 | $2.11B | $169.00M | $3.45 |
| 2023 | $2.19B | $178.00M | $3.36 |
| 2022 | $2.39B | $927.00M | $17.17 |
| 2021 | $2.11B | $220.00M | $3.66 |
| 2020 | $2.02B | $-508.00M | $-8.33 |
| 2019 | $2.15B | $505.00M | $8.15 |
| 2018 | $2.59B | $114.00M | $1.84 |
| 2017 | $2.31B | $1.00M | $0.02 |
| 2016 | $3.02B | $-29.00M | $-0.46 |
| 2015 | $3.42B | $309.00M | $4.61 |
| 2014 | $6.12B | $233.00M | $3.33 |
| 2013 | $6.09B | $683.00M | $8.87 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ASH's reported EPS growth of -29.9% a year over 13 years. Historical EPS growth of -30% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.04
- Implied price
- $0.69
- Return from $72.40
- -60.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.35 — -99.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -67.9% | -66.4% | -65.2% | -64.1% | -63.1% |
| -20.0% | -65.7% | -64.2% | -62.8% | -61.7% | -60.6% |
| -15.0% | -63.6% | -61.9% | -60.5% | -59.3% | -58.2% |
| -10.0% | -61.5% | -59.7% | -58.2% | -56.9% | -55.7% |
| -5.0% | -59.3% | -57.5% | -55.9% | -54.5% | -53.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (36)
- Newsseekingalpha.com·9d ago·Positive
…us On FY 2027 Financial Improvement And Potential Sale Ashland Inc. remains a "Buy," considering its positive financial outlook and interest from possible acquirers. ASH's 4QFY26 revenue and EBITDA largely met expectations; the company is anticipating a turnaround in FY2027 on the back of pricing upside potential and the conclusion of cost restructuring initiatives. According to recent news reports, there are both industry players and private equity firms interested in taking over Ashland.
View source ↗ - Newszacks.com·12d ago·Neutral
ASH Q4 Earnings Miss Estimates Despite Strong Segment Growth Ashland's Q4 fiscal 2026 earnings and sales miss estimates despite volume growth and strong Personal Care demand. The company projects higher sales for fiscal 2027.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that new and updated clinical data from its ongoing Phase 1a…
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What Ashland (ASH) Said on Its Q4 Earnings Call Ashland NYSE: ASH reported higher sales and adjusted earnings for its fiscal fourth quarter, as growth in pharmaceutical and personal care products helped offset weaker manufacturing productivity in Specialty Additives.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026 LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be hel…
View source ↗ - Newsprnewswire.com·18d ago·Positive
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia Long-term follow-up evaluates bone marrow recovery and potential delayed kidney and liver toxicities following Actimab-A plus intensive salvage chemotherapy Findings support development of Actimab-A as a pote…
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its portfolio at the upcoming Ameri…
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026 Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.
View source ↗ - Newsglobenewswire.com·18d ago·Positive
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 14, 2026, from 7:00–8:30 a.m. CT / 8:00–9:30 a.m.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen…
View source ↗ - Newsprnewswire.com·18d ago·Neutral
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH) – Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel ca…
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in the PiNACLE pivotal trial Ronde-cel achieved a 95% overall r…
View source ↗ - Newsglobenewswire.com·18d ago·Positive
…tially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting -- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations, new data to highlight strong activity against additional non-Type 1 mutations -- -- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thr…
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…rapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early …
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting BERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations and one poster presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, which will be held December 12-15, 2026 in New Orleans, Louisiana.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…b to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting Media Release COPENHAGEN, Denmark; November 4, 2026 Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy Six oral presentations include first data disclosure from the Phase 3 EPCORE® DLBCL-4 study eval…
View source ↗ - Newsglobenewswire.com·18d ago·Positive
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 – 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax's scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings, including frontline, post-transplant maintenance, and MRD relapse – – Real-world data showcase compelling results…
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026 New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDA…
View source ↗ - Newszacks.com·19d ago·Negative
Ashland (ASH) Misses Q4 Earnings and Revenue Estimates Ashland (ASH) came out with quarterly earnings of $1.12 per share, missing the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.08 per share a year ago.
View source ↗ - Newszacks.com·19d ago·Neutral
Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
…full‑year fiscal 2027 sales of $1,905-$1,975 million and Adjusted EBITDA of $405-$435 million WILMINGTON, Del., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the fourth quarter of fiscal year 2026, which ended September 30, 2026, together with its fiscal year 2026 results summary and full-year fiscal 2027 outlook.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Ashland sets date for fourth-quarter fiscal 2026 earnings release and conference call webcast WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2026 earnings release at approximately 5 p.m.
View source ↗ - Newszacks.com·54d ago·Positive
ASH's Shares Rally 30% in 6 Months: What's Driving the Upside? Ashland's shares have gained 30.2% in six months as cost cuts, portfolio optimization and a $1-billion buyback support returns.
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
Ashland scales Transformed Vegetable Oils technology platform in crop care, launches agrimer™ eco-disperse OD polymeric dispersant WILMINGTON, Del., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Continuing to scale its Transformed Vegetable Oils (TVO™) technology platform, Ashland Inc. (NYSE: ASH), today announced the global launch of agrimer™ eco-disperse OD TVO™ polymeric dispersant, a patented, nature-based dispersant developed for non-aqueous crop protection formulations.
View source ↗ - Newsseekingalpha.com·65d ago·Positive
Ashland Inc. (ASH) Analyst/Investor Day Transcript Ashland Inc. (ASH) Analyst/Investor Day Transcript
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
UPDATE - Major expansion of Ashland Sawmill announced ASHLAND, Maine, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Irving Forest Products, Inc., a subsidiary of J.D.
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
Major expansion of Ashland Sawmill announced ASHLAND, Maine, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Irving Forest Products, Inc., a subsidiary of J.D.
View source ↗ - Newszacks.com·67d ago·Positive
Here's Why You Should Retain ASH Stock in Your Portfolio Now Ashland is using cost savings, portfolio optimization and buybacks to strengthen margins and free cash flow despite tariff and demand headwinds.
View source ↗ - Newsbenzinga.com·68d ago·Neutral
Watching Ashland; Shares Spike Higher, Traders Circulate Unconfirmed Analyst Report Suggesting Ashland Running A Sales Process; Collecting Bids In September, According To Sources, Apollo Global Management And Carlyle Group Are Among The Private Equity Firms Showing Interest In The Co � 2025 Benzinga.com. Benzinga does not provide investment advice.
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
Ashland Innovation Day to be held September 17, 2026 Wilmington, Del., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host an Innovation Day webcast on September 17, 2026.
View source ↗ - Newsglobenewswire.com·83d ago·Negative
Ashland to host Innovation Day for analysts and investors Wilmington, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a live Innovation Day webcast for analysts and investors from Wilmington, Delaware on September 17, 2026. The event will provide an updated view of Ashland's Technology Platforms, including their commercial progress and scalability. Registration is required and can be accessed from the following link: innovationday26.ashland.com
View source ↗ - Newszacks.com·89d ago·Neutral
ASH Launches Permexa Sodium Caprate to Support Oral Biologics Growth Ashland launches Permexa sodium caprate to support oral peptide and biologic development with enhanced processing and permeability.
View source ↗ - Newsseekingalpha.com·101d ago·Neutral
Ashland Inc.: Activist Pressure Starts To Pay Off Ashland Inc. (ASH) remains a Buy, with the investment case now centered on activist-driven M&A potential and strategic alternatives. Life Sciences and Personal Care segments, comprising 82% of gross EBITDA, continue to deliver growth and margin stability, underpinning valuation. Multiple activist investors, including Standard Industries and Ancora, have driven board changes, capital allocation reviews, and engagement with potential acquirers.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Ashland Now a ‘Gig-Ready' Community From Kinetic's Fiber-Optic Network Expansion More than 75% of homes in community now have access to Kinetic's Multi-Gig, Next-Generation internet 14,000 locations benefit from better internet experience supporting economic growth, telehealth, work, streaming ASHLAND, Ky., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kinetic, the leading insurgent residential and business fiber internet provider, announced today that Ashland is officially recognized as a Kinetic ‘Gig-Rea
View source ↗ - Newsglobenewswire.com·107d ago·Negative
Ashland board authorizes quarterly dividend WILMINGTON, Del., Aug. 07, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.42 cents per share on the company's common stock.
View source ↗
Earnings
Mon, Feb 1(in 2 months)
Consensus estimate $0.38 per share
Typical surprise -7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$1.12 vs $1.27miss
- Tue, Jul 28$1.02 vs $0.98beat
- Tue, Apr 28$0.91 vs $0.97miss
- Mon, Feb 2$0.26 vs $0.23beat
- Tue, Nov 4$1.08 vs $1.17miss
- Tue, Jul 29$1.04 vs $1.15miss
Estimates and results for ASH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ASH officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ASH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
